Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Looks like Ygal wanted some shares?
ATLANTA, GA, April 1, 2015 – GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines for Ebola and ...
GeoVax Provides Update on its HIV Vaccine Program
New Clinical Trial Planned with HVTN and NIH Support; Concept Protocol Approved for HVTN 114
ATLANTA, GA, April 1, 2015 – GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines for Ebola and HIV, today announced that the HIV Vaccine Trials Network (HVTN) has assigned a trial number, HVTN 114, to the next clinical trial of its clade B preventive HIV vaccine candidate.
HVTN 114, entitled: “A Phase 1 clinical trial to evaluate the immunogenicity of AIDSVAX® B/E bivalent gp120 vaccine and MVA/HIV62B in healthy, HIV-1 uninfected adult participants who previously received MVA/HIV62B in DNA/MVA or MVA/MVA regimens in HVTN 205”, is expected to begin enrolling patients during the second half of 2015.
HVTN 114 will enroll up to 100 individuals who participated in the HVTN 205 Phase 2a trial of the GeoVax vaccine (concluded in 2012) and will test the ability of late boosts to increase the antibody responses elicited by the GeoVax vaccine. The late boosts will consist of the GeoVax MVA62B vaccine with or without a gp120 protein vaccine. The gp120 protein, AIDSVAX® B/E, will be supplied by Global Solutions for Infectious Diseases (GSID) and is the same protein used to boost immune responses in the partially successful RV144 vaccine trial in Thailand. Eligible participants in HVTN 114 will receive either (a) another MVA62B boost, (b) a combined boost of MVA62B and AIDSVAX® B/E, or (c) AIDSVAX® B/E alone. HVTN 205 included two different vaccine regimens; HVTN 114 will allow for five separate study groups (up to 20 in each group), and participants will be assigned to each group depending upon their initial vaccine regimen from HVTN 205.
The primary objectives of the trial are (a) to determine the safety of MVA62B and AIDSVAX B/E given separately or together as boost injections after prolonged immunologic rest, to participants who received vaccinations in HVTN 205, and (b) to compare HIV-specific antibody responses to MVA62B and AIDSVAX B/E given separately or together. Secondary objectives are to further characterize HIV-specific antibody and T cell responses to MVA62B and AIDSVAX B/E given separately or together, and to compare durability of the responses at 6 months after the boosts.
Harriet L. Robinson, Ph.D., GeoVax’s Chief Scientific Officer, commented, “Protein boosts were important for the one partially successful HIV vaccine trial, RV144, and we will be testing the effect of the same boost used in RV144 on our vaccine. We believe the HVTN and its funding agency, the National Institute of Allergy and Infectious Disease (NIAID), are taking the prudent step to evaluate the impact of protein boosts in combination with GeoVax vaccines. Information from this trial will inform the design of future, larger, clinical trials. We are pleased that HVTN approved the concept protocol for HVTN 114 and we look forward to taking the steps necessary for initiation of the trial and commencement of patient enrollment.”
About the HVTN
The HIV Vaccine Trials Network (HVTN) is the largest worldwide clinical trials network dedicated to the development and testing of HIV/AIDS vaccines. The HVTN is an international collaboration that conducts all phases of clinical trials, from evaluating experimental vaccines for safety and the ability to stimulate immune responses, to testing vaccine efficacy. Support for the HVTN comes from the U.S. National Institutes of Health (NIH). The Network’s HIV Vaccine Trial Units are located at leading research institutions in 27 cities on four continents. The Network’s headquarters are at the Fred Hutchinson Cancer Research Center in Seattle, Washington.
About Global Solutions for Infectious Diseases
Global Solutions for Infectious Diseases (GSID) is a non-profit global health organization engaged in the development of diagnostic and preventive tools for infectious diseases, including HIV. GSID provides assistance to, and collaborates with, global public health organizations, private foundations, other non-governmental organizations and for-profit entities focused on public health issues and infectious diseases. The focus of GSID is to facilitate the access to affordable health solutions for the benefit of the people most in need, particularly in developing countries. For more information, go to www.gsid.org.
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines against infectious diseases using our novel vaccine platform. Our current development programs are focused on vaccines against Ebola and Marburg viruses, and vaccines against Human Immunodeficiency Virus (HIV). We believe our technology and vaccine development expertise is well-suited for a wide variety of human infectious diseases for which there is an unmet medical need, and we intend to pursue expansion of our product pipeline as resources permit.
Our vaccine platform supports production of non-infectious virus-like particles (VLPs) from the cells of the person receiving the vaccine. Producing non-infectious virus-like particles in the person being vaccinated circumvents the need to purify virus-like particles for inoculation. The production of virus-like particles in the person being vaccinated mimics a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent and control the target infection should it appear.
Clinical trials for GeoVax’s preventive HIV vaccines have been conducted by the US National Institutes of Health-supported HIV Vaccine Trials Network (HVTN) with funding from the National Institute of Allergy and Infectious Disease (NIAID). Overall, GeoVax’s vaccines, in various doses and combinations, have been tested in close to 500 humans. For more information, go to www.geovax.com.
Forward-Looking Statements
Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax can develop and manufacture its vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent HIV or Ebola infection in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. More information about these factors is contained in GeoVax's filings with the Securities and Exchange Commission including those set forth at "Risk Factors" in GeoVax's Form 10-K.
Contact:
Adam S. Holdsworth
PCG Advisory Group
646-862-4607
www.pcgadvisory.com
Copyright © 2015, All rights reserved.
To unsubscribe to this list, contact support
Something to look in too.
GeoVax's Chief Scientific Officer to Speak at World Vaccine Congress
ATLANTA, GA--(NewMediaWire - Mar 31, 2015) - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines for Ebola and HIV using its novel platform technology, today announced that Chief Scientific Officer Dr. Harriet L. Robinson, is invited to speak at the World Vaccine Congress to be held April 7-9, 2015 in Washington, DC. Dr. Robinson is scheduled to speak on April 8, 2015. The title of her talk is "Phase 2 Development of a Prophylactic HIV Vaccine."
The annual World Vaccine Congress, now in its 15th year, provides attendees with the opportunity to hear from leading government stakeholders, business leaders and scientific stakeholders as they continue to enhance the scientific and strategic innovation behind the vaccine industry. To find out more about the World Vaccine Congress event, visit:
http://www.terrapinn.com/conference/world-vaccine-congress-washington/index.stm
U can call this #(678)384-7220. They have been helpful to me in the past.
Sure why not ,, The other press releases have been pretty predictable. But if they really have made this guy some kind of VP, I would hope it means he truly see's something here.
http://www.beyond.com/D0FADBCC-4AD0-4AF4-9371-7432002E4794
What could MOPN possibly have to offer someone with a resume like this?
GeoVax Labs’s “Outperform” Rating Reaffirmed at Zacks (
http://www.wkrb13.com/markets/533318/geovax-labss-outperform-rating-reaffirmed-at-zacks-govx/
need "DFS" back, with all his research ..
GeoVax Appoints Industry Veteran to Its Board of Directors
http://money.cnn.com/news/newsfeeds/articles/marketwire/1183228.htm
JPO Absorbents Announces Addition of Ygal Doron as VP of Business Development
http://www.baystreet.ca/viewarticle.aspx?id=427079
GeoVax Reports 2014 Year-End Financial Results
Progress Report on Ebola/Marburg and HIV Vaccine Programs
http://us7.campaign-archive2.com/?u=e0ab38bd1eb45b58840a9e6ca&id=69c8088862&e=3a00575ad6
If U truly wanted an answer. This is the guy to ask :
jpocompanies@gmail.com
http://www.who.int/mediacentre/factsheets/fs103/en/
You don't really cure ebola , you control it and GOVX believes they have the best control system. IMO
Nice to see this kind of volume.
Excellent...
MOP Environmental Solutions, Inc. First Quarter 2015 Update
http://www.baystreet.ca/viewarticle.aspx?id=426839
I know , just a little frustrating when it gets like this...
Ur preaching to the choir
Here's an idea Yuk,, why not give old Jimb'o a call and tell him how u really feel.
Good to hear from you Sun'b and yes seems like we are in for another round, but of course when I communicate with them , I am told great things are already happening . So we will see. Hope all is well with you and your family.
Just change the names' in this press release and Wa'la déjà vu
http://www.marketwired.com/press-release/mop-environmental-solutions-expands-sales-staff-with-addition-six-new-sales-representatives-1305798.htm
Speaking with the new Managers of MOPN … they think good things are just over the horizon , so they may have convinced some new or maybe old shareholders of great things coming,
Once again. IMO
correct .. Thank you
"All shares of common stock of the Company that shall be outstanding immediately prior to the Effective Time of the Merger shall, by virtue of the Merger, be canceled and converted to the right for each Shareholder of the Company to receive 9,442,811 shares of the common stock, $.001 par value per share, of Purchaser."
After rec. 9.5 million shares in the merger ,I Can't see that 750,000 would mean much.. but just IMO
YES..that last one got my attention .. anyone willing to spend 7 grand at this point in the game, I hope would not just be guessing .
A marathon is still considered a race, the results are just different.
The party was fun while it lasted.
umm.. that's a little interesting,, 2 days in a row...just trying to draw us in ?
MOP Environmental Solutions names VP of International Marketing, Sales and Business Development.
http://www.mopenvironmentalsolutions.com/news/
Great Blog on MOPN'S website.. worth the read
http://www.mopenvironmentalsolutions.com/2015/01/23/question-of-the-week-1232015/
Good for U .. what a difference 1 day can make.
"Yesterday I signed a lease on a 40,000 square foot manufacturing and distribution facility in Trumbull CT" That size of a building, sounds like they have the sales... 1995 you may have jumped ship just a little to soon. IMO http://www.mopenvironmentalsolutions.com/news/
GeoVax Provides Progress Report on Its Ebola Vaccine Program
Ebola Vaccine Demonstrates Production of Virus-Like Particles in Human Cells
January 12, 2015: 09:00 AM ET
http://money.cnn.com/news/newsfeeds/articles/marketwire/1168450.htm
Maybe we are back in another quiet time ,,,because this stock is so top secret and the SEC is watching are every move .We don’t dare say anything until all our cards are in order.. What a bunch of horse sh_t.